Li X.a· Rekep M.a· Tian J.a· Wu Q.a· Chen M.a· Yang S.a· Zhang L.b· Zhang G.a· Qin Y.a· Yu X.a· Xue Q.a· Liu Y.a

Author affiliations

aDepartment of Pharmacology, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
bSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 26, 2022
Accepted: September 18, 2022
Published online: November 24, 2022

Number of Print Pages: 14
Number of Figures: 8
Number of Tables: 1

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

Introduction: Luteolin is a flavonoid polyphenolic compound exerting broad pharmacological and medicinal properties. Diabetes-related obesity increases the total blood volume and cardiac output and may increase the myocardial hypertrophy progression. However, the mechanism of luteolin in diabetic myocardial hypertrophy remains uncertain. Therefore, this study aimed to evaluate whether luteolin improved diabetic cardiomyopathy (DCM) by inhibiting the proteasome activity. Methods: Cardiomyopathy was induced in streptozotocin-treated diabetes mellitus (DM) and db/db mice. Luteolin (20 mg kg−1·day−1) was administrated via gavage for 12 weeks. In vitro, high glucose and high insulin (HGI, glucose at 25.5 mM and insulin at 0.1 µM) inducing primary neonatal rat cardiomyocytes (NRCMs) were treated with or without luteolin for 48 h. Echocardiography, reverse transcription quantitative polymerase chain reaction, histology, immunofluorescence, and Western blotting were conducted. Proteasome activities were also detected using a fluorescent peptide substrate. Results: Luteolin administration significantly prevented the onset of cardiac hypertrophy, fibrosis, and dysfunction in type 1 DM (T1DM) and type 2 DM (T2DM). Compared with DCM mice, luteolin groups showed lower serum triglyceride and total cholesterol levels. Furthermore, luteolin attenuated HGI-induced myocardial hypertrophy and reduced atrial natriuretic factor mRNA level in NRCMs. Proteasome activities were inhibited by luteolin in vitro. Luteolin also reduces the proteasome subunit levels (PSMB) 1, PSMB2, and PSMB5 of the 20S proteasome, as well as proteasome-regulated particles (Rpt) 1 and Rpt4 levels of 19S proteasome. Furthermore, luteolin treatment increased protein kinase B (AKT) and GSK-3α/β (inactivation of GSK-3) phosphorylation. The phosphorylation level of AMPK activity was also reversed after the treatment with luteolin in comparison with the HGI-treated group. Conclusion: This study indicates that luteolin protected against DCM in mice, including T1DM and T2DM, by upregulating phosphorylated protein AMPK and AKT/GSK-3 pathways while decreasing the proteasome activity. These findings suggest that luteolin may be a potential therapeutic agent for DCM.

© 2022 S. Karger AG, Basel

References Tarquini R, Pala L, Brancati S, Vannini G, De Cosmo S, Mazzoccoli G, et al. Clinical approach to diabetic cardiomyopathy: a review of human studies. Curr Med Chem. 2018;25(13):1510–24. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38. Dunlay SM, Givertz MM, David A, Allen LA, Michael C, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2020;7(140):e294–324. Fang F, Li D, Pan H, Chen D, Qi L, Zhang R, et al. Luteolin inhibits apoptosis and improves cardiomyocyte contractile function through the pi3k/akt pathway in simulated ischemia/reperfusion. Pharmacology. 2011;88(3–4):149–58. Li L, Luo W, Qian Y, Zhu W, Qian J, Li J, et al. Luteolin protects against diabetic cardiomyopathy by inhibiting nf-κb-mediated inflammation and activating the nrf2-mediated antioxidant responses. Phytomedicine. 2019;59:152774. Xu T, Li D, Jiang D. Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion. Nutrients. 2012;4(12):2008–19. Taheri Y, Sharifi-Rad J, Antika G, Yılmaz YB, Tumer TB, Abuhamdah S, et al. Paving luteolin therapeutic potentialities and agro-food-pharma applications: emphasis on in vivo pharmacological effects and bioavailability traits. Oxid Med Cell Longev. 2021;2021:1987588. Lang Y, Chen D, Li D, Zhu M, Xu T, Zhang T, et al. Luteolin inhibited hydrogen peroxide-induced vascular smooth muscle cells proliferation and migration by suppressing the src and akt signalling pathways. J Pharm Pharmacol. 2012;64(4):597–603. Wang F, Li D, Chen J, Hu W, Liu Y. Heart protective effects of luteolin on rats with doxorubicin-induced heart failure. Lat Am J Pharm. 2013;32:1313–20. Zhang M, He L, Liu J, Zhou L. Luteolin attenuates diabetic nephropathy through suppressing inflammatory response and oxidative stress by inhibiting stat3 pathway. Exp Clin Endocr Diab. 2021;129(10):729–39. Li M, Li Q, Zhao Q, Zhang J, Lin J. Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences. Int J Clin Exp Patho. 2015;8(9):10112–20. Sun D, Huang J, Zhang Z, Gao H, Li J, Shen M, et al. Luteolin limits infarct size and improves cardiac function after myocardium ischemia/reperfusion injury in diabetic rats. PLoS One. 2012;7(3):e33491. Wang G, Li W, Lu X, Bao P, Zhao X. Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy. J Diabetes Complicat. 2012;26(4):259–65. Gupta A, Behl T, Aleya L, Rahman MH, Yadav HN, Pal G, et al. Role of upp pathway in amelioration of diabetes-associated complications. Environ Sci Pollut R. 2021;28(16):19601–14. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Günther C, et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension. 2008;51(2):302–8. Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC, Martin A. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018;87(1):697–724. Shukla SK, Rafiq K. Proteasome biology and therapeutics in cardiac diseases. Transl Res J Lab Clin Med. 2019;205:64–76. Bozi LHM, Campos JC. Targeting the ubiquitin proteasome system in diabetic cardiomyopathy. J Mol Cell Cardiol. 2017;109:61–3. Schlossarek S, Singh SR, Geertz B, Schulz H, Reischmann S, Hübner N, et al. Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy. Front Physiol. 2014;5:484. Chen DI, Chen MS, Cui QC, Yang H, Dou QP. Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells. Front Biosci Landmrk. 2007;12(5):1935–45. Shen M, Chan TH, Dou QP. Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization. Anti-Cancer Agent Me. 2012;12(8):891–901. Tian JH, Wu Q, He YX, Shen QY, Rekep M, Zhang GP, et al. Zonisamide, an antiepileptic drug, alleviates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 2021;42(3):393–403. Hou N, Mai Y, Qiu X, Yuan W, Li Y, Luo C, et al. Carvacrol attenuates diabetic cardiomyopathy by modulating the pi3k/akt/glut4 pathway in diabetic mice. Front Pharmacol. 2019;10:998. Zhang B, Zhang CY, Zhang XL, Sun GB, Sun XB. Guan Xin Dan Shen formulation protects db/db mice against diabetic cardiomyopathy via activation of Nrf2 signaling. Mol Med Rep. 2021;24(1):531. Wang X, Li D, Fan L, Xiao Q, Zuo H, Li Z. Cape-pno(2) ameliorated diabetic nephropathy through regulating the akt/nf-κb/inos pathway in stz-induced diabetic mice. Oncotarget. 2017;8(70):114506–25. Chen K, Rekep M, Wei W, Wu Q, Xue Q, Li S, et al. Quercetin prevents in vivo and in vitro myocardial hypertrophy through the proteasome-gsk-3 pathway. Cardiovasc Drug Ther. 2018;32(1):5–21. Chen X, Li Y, Yuan X, Yuan W, Li C, Zeng Y, et al. Methazolamide attenuates the development of diabetic cardiomyopathy by promoting β-catenin degradation in type 1 diabetic mice. Diabetes. 2022;71(4):795–811. Wu Q, Tian JH, He YX, Huang YY, Huang YQ, Zhang GP, et al. Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 2021;42(10):1587–97. Deshpande M, Mali VR, Pan G, Xu J, Yang XP, Thandavarayan RA, et al. Increased 4-hydroxy-2-nonenal-induced proteasome dysfunction is correlated with cardiac damage in streptozotocin-injected rats with isoproterenol infusion. Cell Biochem Funct. 2016;34(5):334–42. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. J Biol Chem. 2003;278(24):21517–25. Powell SR, Davies KJA, Divald A. Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations. J Mol Cell Cardiol. 2007;42(1):265–9. Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009;9(1):31–59. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673–751. Hu J, Klein JD, Du J, Wang XH. Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency. Endocrinology. 2008;149(11):5384–90. Luo ZF, Qi W, Feng B, Mu J, Zeng W, Guo YH, et al. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sci. 2011;88(11–12):512–20. Marfella R, Filippo CD, Portoghese M, Siniscalchi M, Martis S, Ferraraccio F, et al. The ubiquitin–proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control. Cardiovasc Pathol. 2009;18(6):332–45. Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y, et al. Therapeutic effect of mg-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of nrf2 and nf-κb. Am J Physiol Heart Circ Physiol. 2013;304(4):H567–78. Chen C, Zou LX, Lin QY, Yan X, Bi HL, Xie X, et al. Resveratrol as a new inhibitor of immunoproteasome prevents pten degradation and attenuates cardiac hypertrophy after pressure overload. Redox Biol. 2019;20:390–401. Xie X, Wang HX, Li N, Deng YW, Bi HL, Zhang YL, et al. Selective inhibition of the immunoproteasome β5i prevents pten degradation and attenuates cardiac hypertrophy. Front Pharmacol. 2020;11:885. Balasubramanyam M, Sampathkumar R, Mohan V. Is insulin signaling molecules misguided in diabetes for ubiquitin–proteasome mediated degradation? Mol Cell Biochem. 2005;275(1–2):117–25. Zhang Y, Huang NQ, Yan F, Jin H, Zhou SY, Shi JS, et al. Diabetes mellitus and alzheimer’s disease: gsk-3β as a potential link. Behav Brain Res. 2018;339:57–65. Farese RV, Sajan MP, Standaert ML. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp Biol Med. 2005;230(9):593–605. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor a. EMBO J. 1990;9(8):2431–8. Lal H, Ahmad F, Woodgett J, Force T. The gsk-3 family as therapeutic target for myocardial diseases. Circ Res. 2015;116(1):138–49. Birnbaum Y, Chen H, Tran D, Nylander S, Ye Y. Ticagrelor and dapagliflozin have additive effects in ameliorating diabetic nephropathy in mice with type-2 diabetes mellitus. Cardiovasc Drug Ther. 2021. Lajoie C, Calderone A, Trudeau F, Lavoie N, Massicotte G, Gagnon S, et al. Exercise training attenuated the pkb and gsk-3 dephosphorylation in the myocardium of zdf rats. J Appl Physiol. 2004;96(5):1606–12. Xu N, Zhang L, Dong J, Zhang X, Chen YG, Bao B, et al. Low-dose diet supplement of a natural flavonoid, luteolin, ameliorates diet-induced obesity and insulin resistance in mice. Mol Nutr Food Res. 2014;58(6):1258–68. Zhang L, Han YJ, Zhang X, Wang X, Bao B, Qu W, et al. Luteolin reduces obesity-associated insulin resistance in mice by activating ampkα1 signalling in adipose tissue macrophages. Diabetologia. 2016;59(10):2219–28. Lee HJ, Lee YH, Park SK, Kang ES, Kim HJ, Lee YC, et al. Korean red ginseng (panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in otsuka long-evans tokushima fatty rats. Metabolism. 2009;58(8):1170–7. Schultze SM, Hemmings BA, Niessen M, Tschopp O. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med. 2012;14:e1. Article / Publication Details

First-Page Preview

Received: May 26, 2022
Accepted: September 18, 2022
Published online: November 24, 2022

Number of Print Pages: 14
Number of Figures: 8
Number of Tables: 1

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.